Skip to main content

Peer Review reports

From: Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy

Original Submission
29 Dec 2017 Submitted Original manuscript
4 Jul 2018 Reviewed Reviewer Report - Paulo Diniz da Gama
8 Oct 2018 Reviewed Reviewer Report - Reviewer 2
30 Jan 2019 Author responded Author comments - Gianluca Furneri
Resubmission - Version 2
30 Jan 2019 Submitted Manuscript version 2
19 Feb 2019 Reviewed Reviewer Report - Reviewer 2
8 Apr 2019 Author responded Author comments - Gianluca Furneri
Resubmission - Version 3
8 Apr 2019 Submitted Manuscript version 3
8 May 2019 Reviewed Reviewer Report - Reviewer 2
12 Jun 2019 Author responded Author comments - Gianluca Furneri
Resubmission - Version 4
12 Jun 2019 Submitted Manuscript version 4
Publishing
17 Jun 2019 Editorially accepted
28 Jun 2019 Article published 10.1186/s12913-019-4264-1

You can find further information about peer review here.

Back to article page